Evommune, Inc. (EVMN) stock
Close on Nov 11, 2026Market cap $312.84MP/E –Yield –
Evommune, Inc. reported revenue of $10.00M for the twelve months to Jun 30, 2026. Free cash flow was -$74.65M. At the latest close the market valued the company at $312.84M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $312.84M
- P/E ratio
- –
- Price to sales
- 31.28
- Price to book
- 1.13
- Dividend yield
- –
- Free cash flow yield
- -23.86%
Fundamentals
- Revenue
- $10.00M
- Net income
- -$94.67M
- EPS, diluted
- -$11.22
- Free cash flow
- -$74.65M
- Book value per share
- $7.68
- Diluted shares
- 36M
Trading
- Next earnings
- Dec 10, 2026 (estimated, after the close)
- Previous close
- $7.84
- Open
- $7.90
- Day's range
- $7.75 – $8.93
- Volume
- 1,432,913
- Average volume (20 days)
- 952,614
- Index membership
- Russell 2000 (since Mar 2026)
- 52-week range
- $4.94 – $33.20
- RSI (14 days)
- 68.4
- Volatility (1 year)
- 120.1%
- Relative volume
- 1.89×
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | EVMN | S&P 500 | Difference | EVMN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +37.9% | -2.4% | +40.3 pts | ||
| 3 months | -39.3% | -1.2% | −38.2 pts | ||
| Year to date | -49.6% | +12.3% | −61.9 pts | ||
| 1 year | -55.7% | +12.4% | −68.2 pts |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Evommune filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Evommune
Pharmaceutical Preparations
Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. The company is advancing a portfolio of product candidates that target key drivers of chronic inflammation, with initial clinical development programs in chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its pipeline features EVO756, an oral small molecule antagonist targeting MRGPRX2 to modulate mast cells and peripheral sensory neurons, and EVO301, an engineered IL-18 binding protein fusion molecule. The company aims to address treatment gaps for patient populations suffering from chronic inflammatory conditions.
Company profile, executives and historyEvommune stock: common questions
What is Evommune's stock price?
EVMN closed at $8.62 on Nov 11, 2026, up 9.95% on the day. Over the past 52 weeks it traded between $4.94 and $33.20.
What is Evommune's market cap?
Evommune was worth $312.84M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is EVMN's P/E ratio?
Evommune lost money over fiscal 2025 (diluted EPS -$11.22), so it has no meaningful P/E ratio.
How much revenue does Evommune make?
Evommune reported revenue of $10.00M for the twelve months to Jun 30, 2026.
Does Evommune pay a dividend?
No. Evommune has not paid a cash dividend over the last twelve months.
When does Evommune report earnings next?
Evommune is expected to report Q3 FY2026 results on Dec 10, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has EVMN stock performed over the past year?
Including dividends, EVMN returned -55.7% over the past year, against +12.4% for the S&P 500.
How many EVMN shares are sold short?
3M shares were sold short at the latest FINRA report, 19.29% of the float, or 3.0 days of average trading volume.
Who are Evommune's competitors?
Companies most similar to Evommune by business, industry and size include HCWB, ROIV, ACRS, ALMS, ZBIO.
See a number that looks wrong?